Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.
Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians.
Kattakuzhy S, et al. Expansion of treatment for hepatitic C virus infection by task shifting to community-based non-specialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167:311-318. doi: 10.7326/M17-0118.
Johnson K, et al. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. J Viral Hepat. 2017;24:966-975. doi: 10.1111/jvh.12731.
Sise M, et al. Effect of Sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 20176;12:1615-1623. doi: 10.2215/CJN.02510317.
Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians:Â The majority of patients infected with HCV can be safely, effectively managed in a primary care setting.HCV viral load after four weeks of treatment with DAAs predicts sustained virologic response (SVR) in a real-world clinical setting.DAA therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney diseaseÂ
Related Content:Hepatitis C